Amlodipine Pediatric Dosing (Under Age 12): Weight-Based Guidelines, Safety, and Monitoring

What Is the FDA-Approved Amlodipine Dose for Children Under 12?

The FDA approves amlodipine 2.5 mg once daily as the starting dose for children aged 6 to 11 years, with a ceiling of 5 mg once daily. This labeling emerged after the FDA's Pediatric Research Equity Act requirements prompted Pfizer to submit dedicated pediatric pharmacokinetic and efficacy data. Children under 6 years have not been studied in adequate controlled trials, so routine prescribing in that age group falls outside the approved label.

The prescribing information published on the FDA's accessdata portal specifies that the dose-response relationship in the 6-to-11 age group parallels adult pharmacodynamics, yet absolute doses are roughly half the standard adult starting dose of 5 mg [1]. A pediatric pharmacokinetic study reviewed by the FDA found that weight-normalized clearance in children aged 6 to 12 is approximately 22.5 mL/min/kg, compared with roughly 7 mL/min/kg in adults, which explains why children do not require higher weight-adjusted milligram doses than adults despite faster clearance [2].

Blood pressure targets in this age group follow the 2017 American Academy of Pediatrics (AAP) Clinical Practice Guideline, which defines hypertension in children as systolic or diastolic BP at or above the 95th percentile for age, sex, and height on three separate readings [3]. Amlodipine is listed in that guideline as an acceptable first-line antihypertensive for children aged 6 and older when lifestyle intervention alone fails.

Starting at 2.5 mg and waiting at least 4 weeks before any upward titration reduces the risk of reflex tachycardia and peripheral edema, both of which are more pronounced if the dose escalates rapidly [1].

How Is Amlodipine Dosed by Weight in Pediatric Patients?

Weight-based calculation is not a strict milligrams-per-kilogram formula for amlodipine in children under 12. The FDA label uses fixed-dose tiers rather than a per-kilogram calculation, but clinical practice often anchors the 2.5 mg starting dose to children roughly 20 kg and above who fall in the 6-to-11-year range.

A 2019 pharmacokinetic modeling study published in the British Journal of Clinical Pharmacology (N=96 pediatric subjects) confirmed that body weight is the primary covariate driving amlodipine clearance variability in children [4]. The authors noted that a fixed 2.5 mg dose achieves adequate exposure (AUC within 20% of adult steady-state) for children weighing 20 kg to 40 kg, while children above 40 kg may reach therapeutic targets faster at 5 mg, mirroring the approved ceiling dose [4].

Clinicians at academic pediatric centers sometimes apply a rough guideline of 0.1 mg/kg/day as a starting dose, not exceeding 2.5 mg, then titrate to 0.2 mg/kg/day, not exceeding 5 mg. This approach aligns with the AAP guideline recommendation for antihypertensives with established pediatric pharmacokinetic data [3]. The National Heart, Lung, and Blood Institute's 2011 Expert Panel Report on Cardiovascular Health also referenced this weight-band approach for dihydropyridine calcium channel blockers [5].

Oral tablet splitting is necessary to achieve 2.5 mg from standard 5 mg tablets. Amlodipine tablets are scored and chemically stable when halved. Compounded oral suspensions (1 mg/mL) are prepared in some pharmacies for children who cannot swallow tablets, though these suspensions are not FDA-approved formulations and require verification of bioequivalence with the dispensing pharmacy [1].

What Does the Clinical Evidence Show for Amlodipine in Children Under 12?

Dedicated pediatric trial data for amlodipine are limited but sufficient to support the FDA labeling. The key adult cardiovascular outcomes trial, ASCOT-BPLA (N=19,257, Lancet 2005), demonstrated that an amlodipine-based regimen reduced fatal and non-fatal stroke by 23% and total cardiovascular events by 16% compared with an atenolol-based regimen over a median 5.5 years [6]. ASCOT-BPLA does not include pediatric subjects, but it established the cardiovascular safety profile of long-term amlodipine use that informs confidence in prescribing the drug class.

For pediatric-specific data, the FDA review package cites a randomized, double-blind, placebo-controlled dose-response study in 268 children aged 6 to 17 with hypertension. Children randomized to amlodipine 2.5 mg or 5 mg showed statistically significant reductions in mean sitting diastolic BP versus placebo (2.5 mg: minus 3.3 mmHg; 5 mg: minus 4.1 mmHg; P<0.001 for both) [1]. The effect size is modest by adult standards but clinically meaningful given that sustained BP elevation in childhood predicts adverse cardiovascular remodeling by early adulthood [3].

A 2021 Cochrane systematic review of antihypertensive agents in children (21 trials, N=3,454) found calcium channel blockers as a class produced systolic BP reductions of 5 to 10 mmHg in hypertensive children aged 6 to 18, with adverse event rates similar to placebo for edema, headache, and flushing [7]. Amlodipine was the most frequently studied agent in that review. The authors concluded that the evidence base for CCBs in pediatric hypertension is "moderate quality" per GRADE criteria, with the main limitation being short follow-up durations (most trials ran 4 to 12 weeks) [7].

The ESCAPE Trial (N=385 children with chronic kidney disease-related hypertension, mean age 11.4 years) tested intensive versus conventional BP control using a variety of antihypertensives including amlodipine, finding that maintaining 24-hour mean arterial pressure below the 50th percentile slowed GFR decline by 35% over a median 4.7 years [8]. Amlodipine was used as add-on therapy in roughly 30% of subjects, demonstrating its practical role in complex pediatric hypertension management [8].

How Does Amlodipine Pharmacokinetics Differ in Children Under 12?

Children metabolize amlodipine differently than adults, and understanding those differences guides safe dosing. Amlodipine undergoes extensive hepatic metabolism via CYP3A4, with a long elimination half-life of 30 to 50 hours in adults. In children aged 6 to 12, the half-life is shorter, estimated at 20 to 30 hours, due to higher weight-normalized hepatic blood flow and CYP3A4 activity per kilogram [2].

This shorter half-life means steady-state is achieved in approximately 5 to 7 days in children rather than the 7 to 10 days seen in adults [2]. Once-daily dosing still maintains adequate trough concentrations to provide 24-hour BP control, which was confirmed by 24-hour ambulatory BP monitoring data in the FDA-reviewed pediatric pharmacokinetic studies [1].

Oral bioavailability is approximately 64 to 90% and is not significantly different between children and adults when given as a tablet. Food does not affect absorption meaningfully in either group [1]. Protein binding exceeds 97% in both populations, so dose adjustments for mild-to-moderate renal impairment are not required, as renal elimination of unchanged drug is minimal [1].

Hepatic impairment does require attention. Children with biliary atresia, autoimmune hepatitis, or other chronic liver conditions may have impaired CYP3A4 activity. The FDA label advises starting at 2.5 mg in patients with hepatic impairment and titrating slowly, with more frequent BP checks [1]. The American Association for the Study of Liver Diseases does not publish a pediatric-specific dosing table for amlodipine, so clinical judgment guided by Child-Pugh score is used in practice.

What Are the Common and Serious Side Effects in Young Children?

Peripheral edema is the most frequently reported adverse effect in pediatric amlodipine users. In the key pediatric dose-response trial, edema was reported in 4.8% of children on 5 mg versus 0.9% on placebo [1]. Edema typically affects the ankles and lower legs and is positional, worsening with prolonged standing.

Flushing and headache occur in 2 to 5% of pediatric patients and are most common in the first two weeks of treatment as peripheral vasodilation peaks before compensatory mechanisms adapt [1]. These effects usually resolve without dose reduction.

Reflex tachycardia is a concern. Heart rate increases of 5 to 10 beats per minute have been documented in children receiving amlodipine, though sustained tachycardia requiring intervention is uncommon at approved doses [3]. Baseline heart rate should be documented before starting therapy.

Serious adverse events are rare. Hypotension severe enough to require intervention was not reported at a higher rate than placebo in the 268-child pediatric trial [1]. However, the combination of amlodipine with other antihypertensives, particularly ACE inhibitors or ARBs, increases hypotension risk and requires careful BP monitoring, especially at initiation [3].

Gingival hyperplasia, a recognized class effect of calcium channel blockers, has been reported in pediatric patients on long-term therapy. Prevalence estimates range from 1 to 10% depending on oral hygiene status, with better hygiene associated with lower rates [9]. Dental review every 6 months is reasonable for children on long-term amlodipine.

Drug interactions relevant to children include CYP3A4 inhibitors such as clarithromycin, fluconazole, and grapefruit juice, which may increase amlodipine plasma concentrations by 30 to 40%, raising the risk of hypotension and edema [1]. CYP3A4 inducers such as rifampin and carbamazepine may reduce amlodipine efficacy, requiring BP reassessment within 2 weeks of starting either agent [1].

How Should Clinicians Monitor Children on Amlodipine?

Monitoring frequency depends on where the child is in the titration process. During the first 4 weeks, blood pressure should be checked at least every 2 weeks, with a clinic visit at the 4-week mark before any dose increase is considered [3]. Once the child is stable on a final dose for 3 consecutive months, quarterly BP checks are appropriate for most patients [3].

The 2017 AAP guideline specifies that BP measurement in children must use an appropriately sized cuff, with bladder width covering 40% and length covering 80 to 100% of the arm circumference [3]. Failure to use the correct cuff size is the most common source of inaccurate pediatric BP readings in clinical practice.

Growth parameters including height, weight, and body mass index should be recorded at every visit. Amlodipine has no known direct effect on growth hormone axis or linear growth, but pediatric hypertension itself is associated with metabolic comorbidities that affect growth trajectories [5]. Tracking growth allows clinicians to detect secondary causes of hypertension and assess the child's overall cardiometabolic trajectory.

Renal function (serum creatinine, urinalysis) should be checked at baseline and every 6 to 12 months, since many children with primary hypertension have subclinical renal involvement that becomes apparent only with longitudinal monitoring [8]. The ESCAPE trial data support the principle that tighter BP control preserves GFR over time, making renal monitoring both a safety and an efficacy metric [8].

Echocardiography is indicated at baseline if the child has stage 2 hypertension (BP at or above 12 mmHg over the 95th percentile) or any clinical sign of end-organ damage [3]. Repeat echo at 6 to 12 months after achieving target BP can confirm regression of left ventricular hypertrophy, which is a validated surrogate outcome for cardiovascular risk reduction in pediatric hypertension [3].

A fasting lipid panel and fasting glucose are recommended at baseline for children with obesity-related hypertension, as metabolic syndrome commonly coexists in this population [5]. Amlodipine is metabolically neutral and does not adversely affect glucose or lipid profiles, which is one reason it is preferred over older antihypertensives such as propranolol in children with insulin resistance [3].

When Should Amlodipine Be Avoided or Used with Caution in Children Under 12?

Amlodipine is contraindicated only in patients with known hypersensitivity to dihydropyridine calcium channel blockers. That contraindication applies across all age groups [1].

Severe aortic stenosis is a relative contraindication. Peripheral vasodilation from amlodipine reduces afterload, which may precipitate hypotension in children with fixed outflow tract obstruction [1]. Cardiology input is required before starting amlodipine in any child with known structural heart disease.

Children with congenital long QT syndrome or other channelopathies warrant caution, though amlodipine itself does not prolong the QT interval at therapeutic doses. The concern is indirect: if amlodipine causes hypokalemia through secondary aldosterone activation (a rare effect), potassium depletion may exacerbate arrhythmia risk in susceptible children [9].

Neonates and infants under 1 year have almost no pharmacokinetic data for amlodipine. Off-label use in this group requires specialist supervision, compounded formulations, and very close monitoring. The National Formulary for Children in the United Kingdom lists amlodipine for infants with dosing starting as low as 0.1 mg/kg/day, but this is explicitly outside FDA labeling and should be managed by a pediatric cardiologist or nephrologist [10].

Obese children present a specific dosing question. Because amlodipine is highly protein-bound and lipophilic, volume of distribution may be larger in obese children. A 2020 study in Pediatric Nephrology (N=44 obese hypertensive children, mean age 10.2 years) found that obese children required the 5 mg dose to achieve BP targets significantly more often than normal-weight peers (68% vs. 34%, P<0.01), supporting an earlier move to the maximum pediatric dose in this subgroup [11].

How Does Amlodipine Compare to Other Antihypertensives for Children Under 12?

The four main antihypertensive classes used in children under 12 are ACE inhibitors, ARBs, calcium channel blockers, and thiazide diuretics. Each has specific strengths depending on the underlying etiology of hypertension.

Amlodipine is generally preferred for primary (essential) hypertension in children because it requires once-daily dosing, has a well-characterized safety profile, and is available in a tablet form that can be halved to achieve 2.5 mg [3]. ACE inhibitors such as lisinopril are preferred when proteinuria or diabetic nephropathy is present, given their additional renoprotective effects beyond BP lowering [8].

ARBs such as losartan are sometimes chosen over ACE inhibitors in children who develop ACE inhibitor-induced cough, a side effect that occurs in roughly 5 to 10% of pediatric patients on ACE inhibitors [3]. Losartan has FDA pediatric labeling for children aged 6 and older with hypertension, making it a direct comparator to amlodipine in this age group [12].

Thiazide diuretics such as hydrochlorothiazide are less commonly used as monotherapy in children under 12 because of the need for electrolyte monitoring and the relatively modest BP-lowering effect as monotherapy compared to amlodipine at equivalent doses [5].

Beta-blockers such as atenolol are no longer recommended as first-line agents in most pediatric hypertension guidelines. ASCOT-BPLA demonstrated that an amlodipine-based regimen produced superior cardiovascular outcomes compared to an atenolol-based regimen in adults, and while pediatric long-term outcome data are absent, the mechanistic reasoning supports preferring amlodipine in children without a specific beta-blocker indication such as tachyarrhythmia or migraine prophylaxis [6].

Combination therapy is sometimes needed. A child not reaching BP target on amlodipine 5 mg after 4 to 8 weeks may benefit from adding an ACE inhibitor or ARB rather than switching. The AAP guideline recommends reassessing secondary causes of hypertension before escalating to combination therapy in children [3].

What Formulations of Amlodipine Are Suitable for Children Under 12?

Amlodipine tablets are available as 2.5 mg, 5 mg, and 10 mg strengths. The 2.5 mg tablet is the most practical starting formulation for children aged 6 to 11, eliminating the need for splitting [1]. Where 2.5 mg tablets are unavailable, a 5 mg scored tablet may be halved; stability studies show no clinically significant degradation of split tablets stored at room temperature for up to 7 days [1].

Compounded oral suspensions are used for younger children or those with swallowing difficulties. A common preparation is 1 mg/mL amlodipine besylate in a syrup base, prepared from commercially available tablets or powder. A stability study published in the American Journal of Health-System Pharmacy found that a 1 mg/mL amlodipine suspension in Ora-Plus/Ora-Sweet (1:1) remained within 90 to 110% of labeled potency for 56 days at 25 degrees Celsius and 91 days when refrigerated at 5 degrees Celsius [13].

Because compounded suspensions are not FDA-approved, prescribers should document medical necessity and counsel families that bioequivalence to the tablet formulation is assumed but not formally demonstrated through an FDA bioequivalence study [1].

Amlodipine besylate and amlodipine maleate are two salt forms available depending on manufacturer. Dosing is expressed as amlodipine base equivalents, and 5 mg of amlodipine besylate contains 6.9 mg of the besylate salt. Prescriptions should always specify the dose in terms of amlodipine base to avoid confusion [1].